Investegate announcements from SparingVision, SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
SparingVision Raises €75 Million Series B to Continue globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
GAMUT
rod-cone dystrophies such as retinitis
pigmentosa
rod-cone dystrophies
today -
Paris,
202
1 - SparingVision (the Company ), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive agreement to acquire GAMUT Therapeutics ( GAMUT ), a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa ( RP ). The acquisition, subject to legal formalities and approval by shareholders of both companies, will be paid mostly in new SparingVision shares and is expected to close in Q2 2021. Further financial terms of the transaction are not disclosed.
SparingVision Conference Participation in H1 2021
SparingVision Conference Participation in H1 2021
Paris, February 16, 2021 - SparingVision ( the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, announces the conferences that its management team will be participating in in the first half of 2021.
OIS Gene Therapy Innovation Showcase
, 18 February
Gene Therapy Outlook panel, Prof. José Alain Sahel, scientific co-founder (2:30-3:30 PM EST)
4th Annual Gene Therapy for Rare Disorders
, 22-25 February
, Dr Dan Chung, Chief Medical Officer, (Feb 22, 3pm EST)
Keeping CMC Activities Off the Critical Path for Gene Therapy Development (Feb 23, 2PM EST) & CMC and Analytical Chair, Dr Rajiv Gangurde, Chief Technology Officer